Phio Pharmaceuticals Corp

NASDAQ:PHIOUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company. The Company's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. It is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. The Company's pipeline is focused on the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its product pipeline includes PH-762 and PH-894. PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cells’ ability to kill cancer cells and is a clinically validated target in immunotherapy. PH-894 is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby affecting the immune system as well as the tumor.

Contact Information

Headquarters

11 APEX DRIVE, SUITE 300A, PMB 2006MARLBOROUGH, MA, United States 01752

Phone

508-767-3861

Fax

508-767-3862

Executives

Chairman of the Board, President, Chief Executive Officer

Robert Bitterman

Lead Independent Director

Robert Ferrara

Independent Director

Patricia Bradford

President, Interim Chief Executive Officer, Director

Geert Cauwenbergh

Independent Director

Jonathan Freeman